Aptose Biosciences, Inc. (APTO)

NASDAQ: APTO · Delayed Price · USD
1.24
0.01 (0.81%)
At close: Jan 26, 2022 4:00 PM
1.22
-0.02 (-1.61%)
After-hours:Jan 26, 2022 5:44 PM EST

Company Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States.

Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome.

It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia.

The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program.

The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Aptose Biosciences, Inc.
Aptose Biosciences Logo
CountryCanada
Founded1986
IndustryBiotechnology
SectorHealth Care
Employees39
CEOWilliam Rice

Contact Details

Address:
251 Consumers Rd Suite 1105
North York, Ontario M2J 4R3
Canada
Phone647 479 9828
Websiteaptose.com

Stock Details

Ticker SymbolAPTO
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0000882361

Key Executives

NamePosition
Dr. William G. Rice Ph.D.Chairman, President and Chief Executive Officer
Dr. Jotin Marango Ph.D., M.D.Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Chief Business Officer
Dr. Rafael Bejar M.D., Ph.D.Senior Vice President and Chief Medical Officer
Roger Davies B.Sc.Vice President of Operations

Latest SEC Filings

DateTypeTitle
Jan 20, 20224Statement of changes in beneficial ownership of securities
Jan 20, 20224Statement of changes in beneficial ownership of securities
Jan 20, 20224Statement of changes in beneficial ownership of securities
Jan 20, 20224Statement of changes in beneficial ownership of securities
Jan 20, 20224Statement of changes in beneficial ownership of securities
Jan 20, 20224Statement of changes in beneficial ownership of securities
Jan 20, 20224Statement of changes in beneficial ownership of securities
Jan 20, 20224Statement of changes in beneficial ownership of securities
Jan 20, 20224Statement of changes in beneficial ownership of securities
Dec 28, 20214/AStatement of changes in beneficial ownership of securities
View All SEC Filings